Search the Newsreel

Earnings Beat: Guardian Pharmacy Services, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Guardian Pharmacy Services, Inc. (NYSE:GRDN) recently surpassed analyst forecasts with strong Q2 results, reporting revenues of US$352m (3.3% above estimates) and EPS of US$0.34 (51% ahead of expectations). Following these results, analysts have updated their models, maintaining revenue estimates for 2026 at US$1.44b but …

Guardian Pharmacy Services (NYSE:GRDN) Stock Rating Upgraded by Wall Street Zen

PharmaCyte Biotech Inc (PMCB) Stock News Today

This article provides current stock information for PharmaCyte Biotech Inc (PMCB), including its latest stock price, daily change, market cap, and links to financial data, analyst ratings, and news. As of the report, PMCB closed at $0.553 with a 1.37% increase, and indicated that …

Why Guardian Pharmacy Services (GRDN) Is Up 10.9% After Raising 2026 Revenue Guidance And Expanding Footprint

Guardian Pharmacy Services (GRDN) saw its stock rise by 10.9% after reporting strong second-quarter 2026 results, including US$351.77 million in sales and US$21.87 million in net income. The company also raised its full-year 2026 revenue guidance to US$1.43 billion–US$1.45 billion and is continuing its …

Guardian Pharmacy Services Q2 Earnings Call Highlights

Guardian Pharmacy Services reported a 2% year-over-year revenue growth to $351.2 million and a 19% increase in adjusted EBITDA to $29.7 million for Q2, despite profitability pressure from Inflation Reduction Act drug pricing reductions. The company raised its 2026 revenue and adjusted EBITDA outlook …

Guardian Pharmacy Services (NYSE:GRDN) Posts Earnings Results, Beats Estimates By $0.03 EPS

Analysts Conflicted on These NA Names: Starz Entertainment Corp (STRZ), Guardian Pharmacy Services, Inc. Class A (GRDN) and MSC Income Fund, Inc. (MSIF)

PharmaCyte Biotech Inc (PMCB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PharmaCyte Biotech Inc (PMCB), detailing future EPS and revenue growth estimates. It includes a snapshot of the company's current stock price, market capitalization, and various financial metrics. The article also lists peer comparisons and indicates that the …

Guardian Pharmacy Services, Inc. Stock 12‑Month Price Target Raised to $48.83, Implies 24% Upside

Guardian Pharmacy Services, Inc. (GRDN) has seen its average 12-month price target raised to $48.83 from $47 by 6 analysts, implying a 24% potential upside from its Aug. 6 closing price. All 6 covering analysts maintain a "Buy" rating for the stock.

Macy's Inc (M) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Macy's Inc (M), indicating an earnings forecast score of 6.29 and a "Hold" rating from 14 analysts. The average price target for Macy's is $23.00, with an expected revenue of $4.81 billion for the next quarter. The …

Guardian Pharmacy Services (NYSE:GRDN) Stock Forecast & Analyst Predictions

Guardian Pharmacy Services (NYSE:GRDN) is projected to see annual earnings growth of 15.4% and revenue growth of 5.7%, with EPS expected to increase by 14.8%. Recent updates include beating analyst forecasts, raising full-year 2026 earnings guidance, and acquiring Wellness Concepts to expand its footprint. …

Form 8K Macy’s For: 7 August By Investing.com

The article reports on Macy's filing of a Form 8K on August 7th. It briefly mentions Macy's stock performance, showing a 1.21% increase. The content appears to be a stub or a placeholder for more detailed information about the 8K filing.

Guardian Pharmacy Services stock hits all-time high at 44.47 USD

Guardian Pharmacy Services Inc. has seen its stock reach an all-time high of $44.47, pushing its market capitalization to $2.5 billion. Despite a remarkable 118.93% increase in stock value over the past year, InvestingPro analysis suggests the stock might be overvalued relative to its …

Guardian Pharmacy Services (NYSE:GRDN) Sets New 12-Month High After Better-Than-Expected Earnings

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

Humacyte, Inc. (Nasdaq: HUMA) announced it will release its financial results for the second quarter and six months ended June 30, 2026, on Wednesday, August 12, 2026. The company will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a …

Biotech company Humacyte to discuss six-month results Aug. 12

Amundi Grows Position in Macy's, Inc. $M

Amundi significantly increased its stake in Macy's, Inc. by 375.7% in the first quarter of 2026, adding 181,684 shares to its portfolio, bringing its total holding to 230,041 shares valued at $4.16 million. This move comes as Macy's stock trades near its one-year high …

Guardian Pharmacy Services shares rise 3% on guidance beat

Guardian Pharmacy Services (NYSE:GRDN) reported strong second-quarter results, exceeding analyst expectations for guidance. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, leading to a 3.22% rise in pre-market trading. Despite some impact from IRA-related pricing reductions, the underlying business momentum remained …

Macy's Inc (M) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Macy's Inc (M), detailing its current price momentum score, support and resistance levels, and a breakdown of various technical indicators and moving averages. It highlights that the stock is currently suitable for range-bound swing trading and offers …

California State Teachers Retirement System Has $5.46 Million Stock Position in Macy's, Inc. $M

The California State Teachers Retirement System increased its stake in Macy's, Inc. by 18.1% in the first quarter, now owning over 300,000 shares valued at approximately $5.46 million. This move is part of broader institutional investor activity, with 87.36% of Macy's stock held by …

Is Guardian Pharmacy (GRDN) Using Tech-Driven Kentucky Expansion to Redefine Its Long-Term Care Edge?

Guardian Pharmacy Services has expanded its presence into Kentucky with a new technology-driven long-term care pharmacy in Lexington, aimed at serving various care settings. This expansion is part of Guardian's strategy to scale its tech-enabled pharmacy network, with the company reaffirming its 2026 revenue …

Guardian Pharmacy Services, Inc. 3Q 2026: Revenue $351.8M, EPS $0.34— 10-Q Summary

Guardian Pharmacy Services, Inc. (GRDN) reported its third-quarter 2026 results, showing revenue of $351.8 million and diluted EPS of $0.34. The company experienced modest top-line growth and stronger profit performance year-over-year, driven by acquisitions, increased prescription volume, and improved gross margins. Guardian Pharmacy Services …

Guardian Pharmacy Services (GRDN) Q2 Earnings and Revenues Top Estimates

Guardian Pharmacy: Q2 Earnings Snapshot

Guardian Pharmacy Services Inc. (GRDN) reported a second-quarter profit of $21.9 million, translating to 34 cents per share, or 29 cents per share when adjusted for one-time gains and costs. This result surpassed Wall Street expectations. The company, which provides pharmacy services to long-term …

Earnings call transcript: Guardian Pharmacy lifts 2026 outlook on Q2 margin gains

Guardian Pharmacy Services reported Q2 results showing a 2% revenue increase to $351.2 million and a 19% adjusted EBITDA increase to $29.7 million, despite pricing pressure from the Inflation Reduction Act. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, signaling stronger …

Guardian Pharmacy (NYSE: GRDN) lifts 2026 revenue and EBITDA outlook

Guardian Pharmacy Services (NYSE: GRDN) reported its Q2 2026 financial results, showing increased revenue and net income, and subsequently raised its full-year 2026 revenue and Adjusted EBITDA guidance. The company also announced the acquisition of Wellness Concepts, a long-term care pharmacy in Virginia, and …

Zacks.com featured highlights Macy's, Pebblebrook, Boise Cascade, Apple Hospitality REIT and PBF Energy

Zacks.com highlights five attractively valued, low price-to-sales (P/S) stocks with strong revenue potential: Macy's, Pebblebrook Hotel Trust, Boise Cascade Co., Apple Hospitality REIT, Inc., and PBF Energy Inc. The article explains why the P/S ratio can be a valuable valuation metric, especially for companies …

First Trust Advisors LP Purchases Shares of 93,677 Guardian Pharmacy Services, Inc. $GRDN

Guardian Pharmacy Services opens long-term care (LTC) pharmacy in Lexington

Guardian Pharmacy Services has opened its first physical location in Kentucky, Guardian Pharmacy of Kentucky, in Lexington. This new state-of-the-art facility will serve residents in various long-term care communities across the state, enhancing service delivery and providing specialized medication management. The expansion aims to …

Macy's, Inc. (M) Hits Fresh High: Is There Still Room to Run?

Macy's (M) stock recently hit a new 52-week high of $26.15, outperforming the retail-wholesale sector and its industry year-to-date. The company has a strong record of beating earnings estimates, and analysts project continued earnings growth for the next fiscal year. With a Zacks Rank …

Macy’s stock hits 52-week high at 26.14 USD

Macy's stock recently achieved a 52-week high of $26.14, closing at $26.13, reflecting a 108% increase over the past year. Despite a suggestion of slight overvaluation by InvestingPro, the retailer maintains an attractive P/E ratio of 10.72 and a PEG ratio of 0.43, indicating …

Quantinno Capital Management LP Reduces Holdings in Macy's, Inc. $M

Quantinno Capital Management LP significantly reduced its stake in Macy's, Inc. by 39.2% in the first quarter, selling over 567,000 shares. This move comes as Macy's reported stronger-than-expected quarterly earnings and revenue, with the company also announcing a quarterly dividend. Analyst ratings for Macy's …

Humacyte, Inc. Revenue Breakdown – NASDAQ:HUMA

Humacyte, Inc. (NASDAQ: HUMA) generated $2.04 million USD in revenue last year, primarily from its Acellular Human Tissues segment. This represents an increase from $1.56 million USD in the previous year, with the United States being the sole contributor to this revenue.

Das prognostizieren Analysten für Redcare Pharmacy NV (ETR:RDC) nach der Veröffentlichung der Ergebnisse für das zweite Quartal

Guardian Pharmacy Services, Inc. (NYSE:GRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Humacyte Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Humacyte (HUMA) has received a notice from Nasdaq stating that its common stock failed to meet the minimum $1.00 bid price requirement for 30 consecutive business days. The company has until January 27, 2027, to regain compliance by maintaining a closing bid price of …